Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Matrix Biol. 2016 Nov 29;60-61:190–205. doi: 10.1016/j.matbio.2016.11.008

Figure 2. Myofibroblastic marker expression of ASCs in 2-D is enhanced with TEV treatment.

Figure 2

a) α-SMA and fibronectin (Fn) of ASCs treated with or without tumor cell-derived EVs (TEVs) as visualized by immunofluorescence. Scale bar = 50 um. b) Quantification of α-SMA levels and c) Fn fiber thickness by image analysis. d), e) Western blots and corresponding densitometric analyses of α-SMA and Fn. * p<0.05.

HHS Vulnerability Disclosure